CARB fees
This article was originally published in The Rose Sheet
Executive Summary
California Air Resources Board estimates fees for volatile organic compound emissions from consumer products will be $86-$90 per ton in fiscal 2004-2005, agency says during Sept. 14 public workshop in Sacramento, Calif. Workshop addressed proposed amendments to consumer product, nonvehicular source and architectural coatings fee regulations, which allow CARB to assess $20 mil. in fees in FY 2004-2005, a $2.6 mil. increase versus last year (1"The Rose Sheet" Sept. 6, 2004, In Brief). Proposal would assess fees on facilities emitting 250 tons or more of VOCs each year. CARB will issue a 45-day notice to the public Oct. 1 announcing the proposal, which will be addressed at Nov. 18 board meeting. Regulation is expected to be effective early next year...
You may also be interested in...
CARB
California Air Resources Board will hold a public workshop to address amendments to consumer products, nonvehicular source and architectural coatings fee regulations Sept. 14 in Sacramento, Calif. Amendments are part of FY 2004-2005 budget, which shifts $2.6 mil. from agency's general fund to support fees. Amount will be assessed on "large facilities that emit 250 tons or more per year of nonattainment pollutants or precursors," CARB says. Remaining $17.4 mil. in fees will be collected on a uniform basis. The agency is permitted to collect fees from consumer product manufacturers that emit 250 tons or more of volatile organic compounds a year under Assembly Bill 10X. CARB also will address proposed fee increases at a Nov. 18 public hearing, the agency notes...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.